Andrew Parker, PhD, executive drug development consultant, Quotient Sciences, explains how AI is integrated into pharmaceutical development.
News|Articles|November 2, 2004
- Pharmaceutical Technology-11-02-2004
- Volume 28
- Issue 11
Searching for a Viable Business Model
Author(s)Jim Miller
What should pharmaceutical companies make of recent corporate developments at several high-profile service providers?
Advertisement
Articles in this issue
almost 22 years ago
Still Waiting for Answersalmost 22 years ago
Method Validation by Phase of Development: An Acceptable Analytical Practicealmost 22 years ago
Comparing and Contrasting Barrier Isolator Decontamination Systemsalmost 22 years ago
November 2004almost 22 years ago
In the Spotlight-November 2004almost 22 years ago
FDA Moves To Implement New GMP PoliciesAdvertisement
Related to this article
2026 approvals, clinical data, and licensing deals are advancing subcutaneous biologics, reducing patient burden, and reshaping biopharma drug strategy.
Shilpa Pharma Lifesciences Limited will launch a new small-molecule CDMO at CPHI Milan in October.
This article explains the 4 shifts enabling faster, lower-risk, commercially successful biologics technology transfer.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Inluriyo-Verzenio Combo Doubles PFS, Adds Oral Complexity
2
Can AI Agents Satisfy CGMP Documentation Requirements?
3
PharmTech Weekly Roundup—September 18, 2026
4
CPHI Milan Brings Back Leadership Summit as Supply Chain and Manufacturing Pressures Ramp Up
5